Literature DB >> 11255264

Cutaneous squamous cell carcinoma and p53 codon 72 polymorphism: a need for screening?

M T Bastiaens1, L Struyk, S P Tjong-A-Hung, N Gruis, J ter Huurne, R G Westendorp, B J Vermeer, J N Bavinck, J ter Schegget.   

Abstract

The association between human papillomavirus (HPV)-associated cervical cancer and cutaneous squamous cell carcinoma and codon 72 polymorphism in the p53 gene is not unequivocal. Especially, it is not known whether carriers of the arginine form have an increased risk of cancer that necessitates screening. The alternative is that the polymorphism is a tumor marker instead of a risk factor. We set out a case-control study to determine the risk of squamous cell carcinoma of the skin in individuals with the p53 codon 72 arginine genotype in order to establish the possible need for screening. The distribution of the different p53 codon 72 genotypes was examined in 86 subjects with a history of cutaneous squamous cell carcinoma and in 168 controls. Additionally, 121 subjects who had had histologically proven basal cell carcinoma and 108 subjects who had had non-familial malignant melanoma were tested. p53 polymorphism was evaluated by polymerase chain reaction (PCR) using DNA samples from peripheral blood lymphocytes. In a subgroup of patients with squamous cell carcinoma and controls, the presence of epidermodyplasia verruciformis human papillomavirus (EV-HPV) DNA was determined in plucked eyebrow hair. Differences in the distributions of the genotypes among cases and controls were calculated, and univariate and multivariate analyses were performed to assess the risk to develop cutaneous squamous cell carcinoma in the presence of the p53 codon 72 arginine genotype. Frequency distributions of the three different genotypes (homozygous for the arginine allele, heterozygous for the two alleles, and homozygous for the proline allele) were similar among the squamous cell carcinoma group and the control group: 47.1%, 46.0% and 6.9% versus 47.8%, 45.8% and 6.4%, respectively. Statistical analysis showed no significant differences between these groups. In patients with squamous cell carcinoma and controls who harbored EV-HPV DNA in their plucked eyebrow hair, similar results were obtained. The distributions of the p53 codon 72 genotypes in the basal cell carcinoma and malignant melanoma group were also not significantly different from the control group. p53 codon 72 arginine homozygosity does not appear to represent a significant risk factor for cutaneous squamous cell carcinoma and screening seems not to be indicated. Mol. Carcinog. 30:56-61, 2001. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11255264     DOI: 10.1002/1098-2744(200101)30:1<56::aid-mc1013>3.0.co;2-2

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  9 in total

1.  Genetic association between p53 codon 72 polymorphism and risk of cutaneous squamous cell carcinoma.

Authors:  Ting Liu; Zeyuan Lei; ZhengYing Pan; Yu Chen; Xiang Li; TongChun Mao; Qian He; Dongli Fan
Journal:  Tumour Biol       Date:  2013-12-20

2.  TP53 codon 72 polymorphism and glioma risk: A meta-analysis.

Authors:  Minghan Shi; Ruishan Huang; Chunying Pei; Xiuzhi Jia; Chuanlu Jiang; Huan Ren
Journal:  Oncol Lett       Date:  2011-12-12       Impact factor: 2.967

3.  p53 Arg72Pro polymorphism and risk of basal cell carcinoma: a meta analysis.

Authors:  Yanli Tian; Li Li; Rongya Yang
Journal:  Int J Clin Exp Med       Date:  2015-02-15

4.  Analysis of Tp53 codon 72 polymorphisms, Tp53 mutations, and HPV infection in cutaneous squamous cell carcinomas.

Authors:  Keith R Loeb; Maryam M Asgari; Stephen E Hawes; Qinghua Feng; Joshua E Stern; Mingjun Jiang; Zsolt B Argenyi; Ethel-Michele de Villiers; Nancy B Kiviat
Journal:  PLoS One       Date:  2012-04-24       Impact factor: 3.240

5.  Increased risk of cutaneous melanoma associated with p53 Arg72Pro polymorphism.

Authors:  Peiliang Geng; Yunmei Liao; Zhihua Ruan; Houjie Liang
Journal:  PLoS One       Date:  2015-03-16       Impact factor: 3.240

6.  The complementary effect of rs1042522 in TP53 and rs1805007 in MC1R is associated with an elevated risk of cutaneous melanoma in Latvian population.

Authors:  Aija Ozola; Dace Ruklisa; Dace Pjanova
Journal:  Oncol Lett       Date:  2019-09-20       Impact factor: 2.967

7.  The association between TP53 Arg72pro polymorphism and non-melanoma skin cancer risk: a meta-analysis including 7,107 subjects.

Authors:  Xueling Yang; Baohong Yang; Ya Liu; Shanshan Xu; Bo Li
Journal:  Indian J Dermatol       Date:  2013-05       Impact factor: 1.494

8.  Arg72Pro polymorphism of TP53 gene and the risk of skin cancer: a meta-analysis.

Authors:  Jun Ye; Xiao-Fen Li; Yong-Dong Wang; Ying Yuan
Journal:  PLoS One       Date:  2013-11-08       Impact factor: 3.240

Review 9.  The role of p53 in the immunobiology of cutaneous squamous cell carcinoma.

Authors:  A P B Black; G S Ogg
Journal:  Clin Exp Immunol       Date:  2003-06       Impact factor: 4.330

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.